Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Būtiski notikumi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2016-01-13 16:22:29 |
Versijas komentārs | |
Teksts |
Riga, Latvia January 13, 2016
JSC ”Grindeks” today announces that on January 12, 2016, it
received the statement of resignation from the position of
Supervisory Council from the Supervisory Council member Uldis
Osis. The Supervisory Council of JSC ”Grindeks” will continue to
operate in a composition as follows:
Chairman of the Council: Kirovs Lipmans,
About “Grindeks”
“Grindeks” is an international, vertically integrated
pharmaceutical company. Main fields of action are research,
development, manufacturing and sales of original products, generics
and active pharmaceutical ingredients. The Group of “Grindeks”
consists of five subsidiary companies in Latvia, Estonia, Russia
and Slovakia as well as representative offices in 13
countries.
“Grindeks” specializes in the heart and cardiovascular, CNS and
anti-cancer medication therapeutic groups. A range of products
covers a successful combination of original products and generics,
with the original products Mildronate® and Ftorafur® and more than
100 forms of generics included therein. Currently “Grindeks”
produces 25 active pharmaceutical
ingredients.
Products of the company are exported to 60 countries and its export
comprises 94% of the total turnover. The main markets are: Russia
and other CIS countries, the Baltic States, the Netherlands,
Germany, Canada, the U.S., France, Ireland and
Japan.
To increase production capacity and develop infrastructure, since
2002 the company has accomplished many significant investment
projects, investing more than 70 million euros over the
years.
Further information: |
Pielikumi |
|